Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Pharmacokinetic studies in migraine: What questions should physicians ask?|
|Citation:||Current Pain and Headache Reports, 2004; 8(3):219-222|
|Publisher:||Current Science Inc.|
|Abstract:||Migraine is a benign self-limiting condition for which the objective of treatment is to maximize the patient’s quality of life by reducing the frequency of attacks and attenuating the pain and suffering of an individual attack as quickly and safely as possible. Evaluating the efficacy of antimigraine treatments, particularly those for the management of the acute attack, is relatively easy because acute symptomatic benefit is the criterion of success. For prophylaxis, therapeutic success generally is measured by relatively simple parameters such as attack frequency. Given that the clinical response to antimigraine therapies relatively is readily assessed by history, the role of more sophisticated investigations such as pharmacokinetic studies may not be immediately clear. This paper aims to provide clinicians with a guide to interpretation of such studies.|
|Description:||Copyright © 2004 by Current Science Inc.|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.